2. Search Result
Search Result
Results for "

vascular proliferation

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

1

Screening Libraries

1

Biochemical Assay Reagents

5

Peptides

1

Inhibitory Antibodies

5

Natural
Products

2

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-151527
    PI3K/Akt/CREB activator 1
    2 Publications Verification

    		 Akt PI3K Epigenetic Reader Domain Neurological Disease
    PI3K/Akt/CREB activator 1 (compound AE-18) is a potent, orally active PI3K/Akt/CREB activator. PI3K/Akt/CREB activator 1 promotes neuronal proliferation, induced differentiation of Neuro-2a cells into a neuron-like morphology, and accelerated the establishment of axon-dendrite polarization of primary hippocampal neurons through upregulating brain-derived neurotrophic factor via the PI3K/Akt/CREB pathway. PI3K/Akt/CREB activator 1 can be used in research of vascular dementia (VaD) .
    PI3K/Akt/CREB activator 1
  • HY-N0590
    Corynoxeine
    5 Publications Verification

    		 ERK Cardiovascular Disease
    Corynoxeine, isolated from the hook of Uncaria rhynchophylla, is a potent ERK1/ERK2 inhibitor of key PDGF-BB-induced vascular smooth muscle cells (VSMCs) proliferation.
    Corynoxeine
  • HY-N2484
    Methylnissolin

    Astrapterocarpan

    		 PDGFR ERK Cardiovascular Disease
    Methylnissolin (Astrapterocarpan), isolated from Astragalus membranaceus, inhibits platelet-derived growth factor (PDGF)-BB-induced cell proliferation with an IC50 of 10 μM. Methylnissolin inhibits PDGF-BB-induced phosphorylation of extracellular signal-regulated kinase 1/2 (ERIC1/2) mitogen-activated protein (MAP) kinase. Methylnissolin inhibits PDGF-BB-induced vascular smooth muscle cell proliferation by inhibition of the ERK1/2 MAP kinase cascade .
    Methylnissolin
  • HY-12514
    NK3201

    		Ser/Thr Protease
    NK3201 is an orally active chymase inhibitor (IC50: 2.5, 1.2, and 28 nM for human, dog and hamster chymase). NK3201 inhibits Bleomycin (HY-17565)-induced pulmonary fibrosis. NK3201 inhibits vascular proliferation in grafted vein .
    NK3201
  • HY-117836
    FAK-IN-16

    		FAK Cancer
    FAK-IN-16 (compound OXA-11) is an orally active, selective focal adhesion kinase (FAK) inhibitor with an IC50 of 1.2 pM. FAK-IN-16 inhibits FAK phosphorylation at pFAK[Y397] and pFAK[Y861]. FAK-IN-16 slows tumor growth and reduces tumor vascularity, invasion. FAK-IN-16 potentiates effects of Cisplatin (HY-17394) on tumor cell proliferation and apoptosis in vitro and anti-tumor actions in mice .
    FAK-IN-16
  • HY-131895
    5,6-Dehydroarachidonic acid

    		Lipoxygenase Inflammation/Immunology
    5,6-Dehydroarachidonic acid is a 5-lipoxygenase (Lipoxygenase) inhibitor that inhibits the biosynthesis of leukotrienes. However, 5,6-Dehydroarachidonic acid had no effect on vascular cell proliferation .
    5,6-Dehydroarachidonic acid
  • HY-A0117
    Temocaprilat

    Temocapril diacid; Temocaprilate; RS 5139

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Temocaprilat (Temocapril diacid) is an inhibitor of angiotensin-converting enzyme (ACE). Temocaprilat alleviates the inhibitory effect of high glucose on the proliferation of aortic endothelial cells. Temocaprilat has potential applications in hypertension and vascular inflammation .
    Temocaprilat
  • HY-122622
    PF-04471141 hydrochloride

    		Others Others
    PF-04471141 (hydrochloride) is a compound that regulates intracellular cAMP and cGMP concentrations. It is a PDE1 inhibitor and has different effects on different PDE enzymes in regulating intracellular signaling molecule concentrations and cell proliferation in vascular smooth muscle cells.
    PF-04471141 hydrochloride
  • HY-167736
    (2R)-Naroparcil

    		Others Others
    (2R)-Naroparcil is an isomer of Naroparcil, a 4-methylumbelliferyl beta-D-xyloside analog that plays a role in promoting vascular smooth muscle cell proliferation and has been shown to inhibit thrombus formation in the Wessler slough model.
    (2R)-Naroparcil
  • HY-N0590R
    Corynoxeine (Standard)

    		ERK Cardiovascular Disease
    Corynoxeine (Standard) is the analytical standard of Corynoxeine. This product is intended for research and analytical applications. Corynoxeine, isolated from the hook of Uncaria rhynchophylla, is a potent ERK1/ERK2 inhibitor of key PDGF-BB-induced vascular smooth muscle cells (VSMCs) proliferation.
    Corynoxeine (Standard)
  • HY-P0012A
    Aviptadil acetate
    1 Publications Verification

    Vasoactive Intestinal Peptide acetate salt (human, rat, mouse, rabbit, canine, porcine)

    		 SARS-CoV Infection Inflammation/Immunology
    Aviptadil acetate is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil acetate induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil acetate can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .
    Aviptadil acetate
  • HY-157148
    1D228

    		c-Met/HGFR Trk Receptor Cancer
    1D228 is a c-Met/TRK inhibitor with antitumor activity. 1D228 inhibits cyclin D1 to induce G0/G1 arrest and inhibit cancer cell proliferation and migration. 1D228 can be used in the study of gastric, liver and vascular tumors .
    1D228
  • HY-116431
    I-BOP

    		Prostaglandin Receptor Cardiovascular Disease Neurological Disease
    I-BOP is an agonist for thromboxane A2 receptor (TP) with a KD of 0.61 nM. I-BOP promotes proliferation through activation of PI3K pathway in vascular smooth muscle . I-BOP dose-dependently biphasicly affects the excitatory postsynaptic potential (e.p.s.p.) in hippocampal neurons .
    I-BOP
  • HY-112350
    AGL 2043

    		PDGFR FLT3 Cancer
    AGL 2043 is an effective inhibitor of PDGFR (IC50=0.8 μM) and TEL-PDGFR kinases, as well as FLT3 and KIT kinases. AGL 2043 can effectively inhibit porcine cardiac smooth muscle cell proliferation and balloon-induced vascular stenosis, and is suitable for development as an anti-restenotic and anticancer agent .
    AGL 2043
  • HY-B0715
    Pentoxifylline
    5+ Cited Publications

    BL-191; PTX; Oxpentifylline

    		 Phosphodiesterase (PDE) Autophagy HIV Cardiovascular Disease Cancer
    Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation .
    Pentoxifylline
  • HY-P0012
    Aviptadil
    1 Publications Verification

    Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine)

    		 SARS-CoV Infection Inflammation/Immunology
    Aviptadil is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .
    Aviptadil
  • HY-112417
    Ki11502

    		PDGFR FLT3 Apoptosis Akt PERK Bcl-2 Family Cardiovascular Disease Cancer
    Ki11502 is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the activity of PDGF β/α receptors with IC50 values less than 10 nM. Ki11502 selectively inhibits PDGF β receptor phosphorylation, proliferation, and proteoglycan synthesis in human vascular smooth muscle cells. Ki11502 can induce Apoptosis) and exhibits profound antiproliferative effects on select subsets of leukemia, including those with Imatinib (HY-15463) resistant mutations. Ki11502 is highly suitable for studying the role of PDGF in vascular diseases, particularly the role of proteoglycans in atherosclerosis .
    Ki11502
  • HY-W753806
    Doxazosin hydrochloride

    UK 33274 hydrochloride

    		 Others Cardiovascular Disease
    Doxazosin hydrochloride (UK 33274 hydrochloride) is a compound used to inhibit hypertension and prostate hyperplasia, with activity that inhibits postsynaptic α1-adrenoceptors on vascular smooth muscle. Doxazosin hydrochloride can cause vasodilation, thereby reducing peripheral vascular resistance. Doxazosin hydrochloride was found to inhibit the proliferation and migration of hepatic stellate cells in a mouse liver fibrosis model. Doxazosin hydrochloride regulates fibrosis, autophagy, and apoptosis of hepatic stellate cells by activating the PI3K/Akt/mTOR signaling pathway. Doxazosin hydrochloride also blocks autophagic flux and induces apoptosis of hepatic stellate cells .
    Doxazosin hydrochloride
  • HY-B0023
    Azelnidipine
    2 Publications Verification

    CS 905

    		 Calcium Channel MEK Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Azelnidipine (CS 905) is a dihydropyridine calcium channel blocker that is effective orally. Azelnidipine inhibits the intracellular calcium ion flow and lower blood pressure by selectively blocking L-type calcium channel on the membrane of vascular smooth muscle. Azelnidipine inhibits esophageal squamous cell carcinoma proliferation by targeting MEK1/2. Azelnidipine also has anti-inflammatory, antioxidant and neuroprotective effects .
    Azelnidipine
  • HY-B0715S
    Pentoxifylline-d6

    BL-191-d6; PTX-d6; Oxpentifylline-d6

    		 Phosphodiesterase (PDE) Autophagy HIV Cardiovascular Disease Cancer
    Pentoxifylline-d6 is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].
    Pentoxifylline-d6
  • HY-B0715S2
    Pentoxifylline-d5

    BL-191-d5; PTX-d5; Oxpentifylline-d5

    		 Phosphodiesterase (PDE) Autophagy HIV Cardiovascular Disease Cancer
    Pentoxifylline-d5 is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].
    Pentoxifylline-d5
  • HY-P99333
    Volociximab

    M200; Eos 200-4

    		 Integrin Cardiovascular Disease Cancer
    Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC50=0.2 nM). Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs) .
    Volociximab
  • HY-N2692
    6,8-Diprenylgenistein

    		Others Cancer
    6,8-Diprenylgenistein is an isoflavone compound isolated from Cudrania tricuspidata. 6,8-Diprenylgenistein has antimicrobial and anti-obesity activity. 6,8-Diprenylgenistein inhibits the proliferation, migration and tubular formation of HLMEC induced by recombinant human vascular endothelial growth factor-A. 6,8-Diprenylgenistein can be used to study new therapeutic drugs for the prevention and treatment of oral cancer metastasis .
    6,8-Diprenylgenistein
  • HY-B0715R
    Pentoxifylline (Standard)

    BL-191 (Standard); PTX (Standard); Oxpentifylline (Standard)

    		 HIV Autophagy Phosphodiesterase (PDE) Cardiovascular Disease Cancer
    Pentoxifylline (Standard) is the analytical standard of Pentoxifylline. This product is intended for research and analytical applications. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation .
    Pentoxifylline (Standard)
  • HY-116452
    YLT192

    		Others Cancer
    YLT192 is an orally active and highly bioavailable VEGFR2 inhibitor with potent anti-angiogenic activity and anti-tumor efficacy. YLT192 significantly inhibited the kinase activity of VEGFR2 and inhibited the proliferation, migration, invasion and tube formation of human umbilical cord vascular endothelial cells. YLT192 also inhibited VEGF-induced VEGFR2 phosphorylation and its downstream signaling regulators. YLT192 also showed the ability to inhibit angiogenesis in vivo in zebrafish embryo models and alginate-coated tumor cell experiments. YLT192 can directly inhibit the proliferation of cancer cells and induce their apoptosis .
    YLT192
  • HY-126849
    3-Morpholinosydnonimine

    SIN-1; Linsidomine

    		 MDM-2/p53 Reactive Oxygen Species Apoptosis Annexin A Glutathione Reductase Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    3-Morpholinosydnonimine (SIN-1) is a spontaneous ROS/RNS generator and peroxynitrite donor. 3-Morpholinosydnonimine induces oxidative stress-induced chondrocyte apoptosis and necrosis. 3-Morpholinosydnonimine inhibits the migration, proliferation and neointima formation of vascular smooth muscle cells by inhibiting the expression of annexin A2. In addition, low doses of 3-Morpholinosydnonimine shows protective effects on Zn 2+ treated nerve cells .
    3-Morpholinosydnonimine
  • HY-162888
    WQ-C-401

    		PDGFR ERK Cardiovascular Disease
    WQ-C-401 is an orally active platelet-derived growth factor receptor (PDGFR) inhibitor. WQ-C-401 inhibits cell proliferation by blocking PDGFR autophosphorylation in a concentration-dependent manner, with EC50 values of 3.5 nM for PDGFRα Y849 and 5.8 nM for PDGFRβ Y1021. Additionally, WQ-C-401 can inhibit PASMCs proliferation and migration by blocking PDGF-BB-induced ERK1/2 phosphorylation, reducing collagen I synthesis, and increasing α-SMA expression, thereby preventing pulmonary vascular remodeling. WQ-C-401 holds promise for research in the field of pulmonary arterial hypertension .
    WQ-C-401
  • HY-164551
    YLL545

    		VEGFR STAT ERK Apoptosis Cancer
    YLL545 is a type of vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor. YLL545 can inhibit VEGF-induced phosphorylation of VEGFR2 and the activation of downstream signaling factors (like phosphorylated STAT3 and phosphorylated ERK1/2) in human umbilical vein endothelial cells (HUVEC). YLL545 can suppress the proliferation, migration, invasion, and angiogenesis of HUVEC. YLL545 can induce apoptosis in breast cancer mice and inhibit tumor growth .
    YLL545
  • HY-10338A
    Foretinib phosphate

    		c-Met/HGFR VEGFR Cancer
    Foretinib phosphate is an orally bioavailable small molecule with potential anti-tumor activity. Foretinib phosphate can selectively inhibit hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), thereby potentially inhibiting tumor angiogenesis, tumor cell proliferation and metastasis. Foretinib phosphate shows different anti-cancer activity from cabozantinib in lung cancer cells and has stronger inhibitory effects on targets such as MEK1/2, FER and AURKB .
    Foretinib phosphate
  • HY-116116
    Tafetinib

    SIM010603

    		 c-Kit RET VEGFR Cancer
    Tafetinib (SIM010603) is an oral multi-targets receptor tyrosine kinases inhibitor. Tafetinib inhibitsstem cell factor receptor (Kit),vascular endothelial growth factor receptor-2 (VEGFR-2),platelet-derived growth factor receptor-β (PDGFR-β),glial cell line-derived neurotrophic factor receptor (Rearranged during Transfection; RET), andFms-like tyrosine kinase-3 (FLT3)withIC50values between 5.0 and 68.1 nmol/l. Tafetinib inhibits the phosphorylation ofPDGFR-βandVEGFR-2. Tafetinib inhibits endothelial cell proliferation, endothelial cells chemotaxis, and corneal angiogenesis .
    Tafetinib
  • HY-13559
    Atiprimod

    Azaspirane

    		 Apoptosis Cancer
    Atiprimod (Azaspirane) is an orally bioavailable small molecule with antitumor, anti-inflammatory, and anti-angiogenic activities. Atiprimod blocks the signaling pathways of interleukin-6 and vascular endothelial growth factor (VEGF) by inhibiting the phosphorylation of signal transducer and activator of transcription 3 (STAT3). Atiprimod also downregulates the anti-apoptotic proteins Bcl-2, Bcl-XL, and Mcl-1, thereby inhibiting cell proliferation, inducing cell cycle arrest, and inducing apoptosis. Atiprimod triggers persistent ER stress-mediated apoptosis in breast cancer cells by activating the PERK/eIF2α/ATF4/CHOP axis and inhibiting the nuclear translocation of STAT3/NF-κB transcription factors .
    Atiprimod
  • HY-105168
    TAK 044

    		Endothelin Receptor Cardiovascular Disease
    TAK 044 is an antagonist of Endothelin Receptor. TAK 044 strongly inhibits ET-induced deterioration in various animal models. TAK 044 can be used in study ET-related diseases such as acute myocardial infarction,acute renal failure, acute hepatic malfunction, and subarachnoid hemorrhage .
    TAK 044
  • HY-19471
    (rac)-ZK-304709

    		Others Cancer
    (rac)-ZK-304709 is an isomer of ZK-304709. It is a first-in-class oral multi-target tumor growth inhibitor that inhibits multiple cell cycle-dependent kinases (Cdks), vascular endothelial growth factor receptor kinases (VEGF-RTKs), and platelet-derived growth factor receptor kinase β (PDGF-RTKβ). (rac)-ZK-304709 can dose-dependently inhibit the proliferation and colony formation of neuroendocrine tumor (NET) cells. It directly acts on NET cells by inducing G2 cell cycle arrest and apoptosis, while reducing the expression of MCL1, survivin, and HIF1α. In an orthotopic BON tumor model, (rac)-ZK-304709 reduced primary tumor growth by 80% and reduced tumor microvascular density. These results suggest that (rac)-ZK-304709 can effectively control tumor growth by inducing apoptosis and inhibiting tumor-induced angiogenesis, and may be a potential agent for the treatment of NET.
    (rac)-ZK-304709

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: